{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34","upperLimit":"60","value":"45"},{"groupId":"OG001","lowerLimit":"41","upperLimit":"69","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"An event is defined as relapse or transplant-related mortality. Relapse is defined in section 3.3 study protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tacro-MTX/Sirolimus GVHD Prophylaxis","id":"OG000","title":"Experimental"},{"description":"Tacro-MTX GVHD Prophylaxis","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"Two ineligible patients on experimental arm excluded from analysis.","reportingStatus":"POSTED","timeFrame":"at 2 years","title":"Estimated Percentage of Participants With Event Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}